Neurorehabilitation Technology Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Neurorehabilitation Technology Market in 2026?

USD 1,314.6 million in 2026 and USD 2,864.5 million by 2036 at an 8.1% CAGR.

Demand in the neurorehabilitation technology market is anticipated to push valuation from USD 1,314.6 million in 2026 to USD 2,864.5 million by 2036, expanding at an 8.1% CAGR over the forecast period. Neurological teams create the purchasing mechanism by seeking repeatable therapy intensity without adding equivalent clinician hours across scheduled sessions. The World Health Organization reported in May 2025 that an estimated 2.6 billion people worldwide may benefit from rehabilitation services. Providers therefore evaluate whether medical rehabilitation robotics can extend task repetition while preserving therapist control and measurable progression. Comparable robotic rehab tools matter most when their data informs treatment changes instead of producing isolated activity counts. Capital spending becomes defensible when hospitals connect patient selection with scheduled utilization and documented functional outcomes.

National purchasing routes remain materially different despite similar clinical goals across hospital and community rehabilitation services. United States providers must connect device use with coded therapy services and complete documentation across each billed episode. Japanese recovery hospitals concentrate intensive treatment inside structured wards that rely on multidisciplinary staffing and defined clinical schedules. Systems combining neurostimulation systems with motor training require additional protocol control because stimulation settings create separate safety responsibilities. Products using brain-computer interfaces require signal calibration and patient-specific training that can lengthen implementation during routine clinical use. Manufacturers therefore compete through workflow design and clinical support rather than device specifications alone during institutional procurement. Commercial adoption strengthens when local service teams reduce downtime and translate device output into ordinary treatment decisions.

Summary of the Neurorehabilitation Technology Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Neurology services create measurable spending when technology increases therapeutic repetition without weakening clinical control or documentation quality. Hospitals prioritize systems that fit scheduled therapy blocks and reduce unproductive setup time during routine neurological rehabilitation. Clinicians value objective progression data when measurements support treatment changes and strengthen communication across multidisciplinary care teams. Service coverage affects purchasing because equipment downtime can interrupt intensive programs and weaken expected capacity gains across treatment schedules. Reimbursement fit matters when device-assisted sessions remain traceable within existing therapy documentation and billing requirements for each patient episode.
Product and Segment View	The product architecture combines physical assistance with software that measures performance and guides each subsequent treatment session. Robotic rehabilitation is estimated to hold 36.4% of technology revenue during 2026 through repeatable motor-training applications. Stroke rehabilitation is projected to represent 38.7% of application revenue through sustained gait and upper-limb recovery needs. Hospitals are expected to account for 39.8% of end-user revenue through specialist staffing and capital purchasing capacity. Hardware is forecast to capture 37.0% of product-type revenue despite installation and maintenance requirements that increase ownership costs.
Geography and Growth Outlook	Country performance differs through reimbursement rules and specialist capacity rather than one uniform adoption route across national care systems. The UK is forecast to expand at 9.7% CAGR through 2036, driven by coordinated stroke pathways and public purchasing structures. The USA is projected to record 8.8% CAGR as coverage documentation and provider scale shape adoption decisions. Japan is estimated to post 8.6% CAGR during the forecast period, driven by recovery wards and domestic medical-device pathways that concentrate intensive care. Germany and South Korea require dependable local service because distributed facilities and selective coverage create implementation friction.
Competitive Landscape	Competition separates broad robotic ecosystems from focused exoskeleton platforms and software-led neurological therapy systems serving different clinical settings. DIH through Hocoma and Tyromotion compete through broad portfolios spanning gait and upper-limb therapy with clinical integration services. Fourier Rehab and CYBERDYNE combine proprietary robotics with connected feedback across several neurological treatment pathways and patient groups. Ekso Bionics and Lifeward focus on wearable mobility systems supported by training and regional reimbursement development. MindMaze Therapeutics and Neuro Rehab VR emphasize software-led therapy across clinical and home rehabilitation settings.
Analyst Perspective	Executives must balance therapy capacity against implementation burden because technical performance cannot guarantee routine clinical utilization across ordinary schedules. A pilot should define patient eligibility and functional measures before equipment enters a crowded rehabilitation schedule with clear staff ownership. Commercial evaluation should separate patient outcomes from device utilization because each measure answers a different investment question. Service contracts need to specify response times and replacement routes so downtime risk remains financially accountable throughout scheduled operating hours. - Anurag Sharma, Principal Analyst at Future Market Insights

Source: FMI’s proprietary forecasting model and primary research

How is the neurorehabilitation technology market segmented?

The neurorehabilitation technology industry is segmented by technology, application, end user, product type, and region.

Technology separates robotic rehabilitation from brain-computer interfaces and neurostimulation systems together with virtual reality rehabilitation within clinical programs. Application analysis distinguishes stroke rehabilitation from spinal cord injury and traumatic brain injury programs alongside Parkinson’s disease rehabilitation. End-user categories separate hospitals from rehabilitation centers and specialty clinics together with home care settings across distinct care environments. Product type divides revenue among hardware and software alongside services and wearable systems that carry different support requirements. Regional analysis compares purchasing routes across North America and Latin America together with Europe and Asia-Pacific markets. The framework measures commercially available equipment and associated software or services that directly support neurological rehabilitation delivery.

How do robotic systems change therapy capacity within the Technology category?

Robotic rehabilitation systems deliver guided movement with adjustable assistance across repeated sessions under therapist supervision. Wearable exoskeleton systems and stationary designs address different patient needs and room constraints within the same clinical program. A randomized trial published by the Annals of Indian Academy of Neurology in January 2026 followed 42 subacute ischemic stroke patients in India through 15 robot-assisted sessions. The results support representative clinical validation before hospitals assign robotic capacity across broader neurological caseloads.

• Within technology, robotic rehabilitation is projected to account for 36.4% share in 2026 through its direct role in repetitive motor training. Physical assistance and session measurement allow clinicians to adjust support across recovery stages without replacing therapist judgment during progression decisions.
• Rehabilitation departments favor modular robotic platforms that serve several neurological conditions without frequent hardware changes across ordinary schedules. Adjustable supports improve flexibility across inpatient and outpatient programs while fitting time and trained supervision remain necessary for safe daily utilization during crowded treatment schedules.

Why does stroke rehabilitation anchor the Application category?

Stroke programs require sustained motor practice across patients whose strength and cognition change throughout each recovery phase. Treatment pathways often span inpatient rehabilitation and outpatient follow-up so clinicians need comparable records across several provider settings. Flexible protocols remain necessary because impairment patterns differ markedly among patients who share similar diagnoses and recovery timelines. Technologies gain practical value when they standardize repetition without narrowing individualized progression decisions across successive recovery stages.

• By application, stroke rehabilitation is estimated to hold 38.7% share in 2026 owing to broad gait and upper-limb recovery needs. The Centers for Disease Control and Prevention reported in October 2024 that more than 795,000 people experience stroke annually in the United States. Recurring clinical volume supports device use across multidisciplinary pathways in hospital and outpatient rehabilitation settings.
• Stroke teams favor platforms that combine motor training with cognitive feedback and progress reporting across successive care settings. Connected digital therapeutics extend assigned practice beyond supervised sessions and preserve measurable adherence for later clinical review across several recovery phases without creating separate records.

What makes hospitals the primary End User for complex systems?

Hospitals concentrate neurologists and rehabilitation physicians alongside therapists who can screen patients and manage contraindications across complex pathways. Biomedical engineering departments provide installation oversight and continuing maintenance for regulated rehabilitation equipment across clinical facilities. Clinical governance coordinates training and secure data access with escalation responsibilities across each neurological service line. Purchasing remains sensitive to room availability and staff time because specialized systems must fit existing treatment schedules.

• Hospitals are forecast to hold 39.8% of end-user revenue in 2026 through specialist staffing and higher capital capacity. Their position also reflects access to inpatient neurological cases requiring intensive supervised rehabilitation across several clinical disciplines and coordinated technical support functions.
• Documentation quality affects hospital adoption because technology cannot create reimbursable care without records for each treatment episode. The Centers for Medicare & Medicaid Services reported in June 2026 that insufficient documentation caused 84.3% of improper CORF payments during the United States 2024 reporting period. Hospital leaders need device records connecting treatment activity with each therapist’s clinical purpose and progression decision.

How does hardware shape deployment within the Product Type category?

Hardware determines physical assistance and sensing accuracy across devices interacting directly with impaired movement during supervised therapy. Robotic joints and wearable frames require patient-specific fitting that software controls cannot replace during clinical preparation. Headsets and sensors create ergonomic and cybersecurity requirements in shared hospital environments during extended sessions. The United States Food and Drug Administration reported in June 2026 that probable national risks for augmented and virtual reality medical devices include cybersickness and strain. Procurement teams must evaluate physical safety and digital controls within one implementation plan for each facility.

• By product type, hardware is forecast to represent 37.0% in 2026 driven by the cost of actuators and sensing components within protected treatment systems. Installation and safety validation increase the initial budget beyond the device price and create continuing maintenance obligations.
• Providers compare fixed robotic stations with wearable medical robots that can serve different rooms and patient pathways. Portable designs improve scheduling flexibility across shared equipment pools although battery management and fitting time can limit daily throughput during scheduled treatment blocks.

What are the drivers, restraints, and opportunities in the neurorehabilitation technology market?

Neurological disease burden supports demand for repeatable rehabilitation technology; workforce and reimbursement constraints limit routine deployment; connected care creates an opportunity for supervised home practice.

• Driver: Neurological services need scalable methods that increase motor practice and preserve measurable performance across extended recovery pathways.
• Restraint: Equipment cost and specialist training can prevent technically capable systems from reaching dependable daily utilization across routine clinical schedules.
• Opportunity: Connected therapy can link supervised treatment with structured home practice and remote clinical review across longer recovery pathways.

Neurological disease burden creates sustained pressure on rehabilitation services across conditions requiring repeated motor or cognitive therapy. The World Health Organization reported in March 2024 that more than three billion people lived with a neurological condition worldwide during 2021. Rehabilitation providers therefore need technologies that increase treatment intensity without removing clinical judgment or patient-specific progression. Purchasing becomes defensible when measurable practice improves staffing capacity and documented outcomes across ordinary neurological services.

Specialist workforce shortages limit utilization because advanced systems require trained operators and dependable referral pathways across multiple care settings. The World Health Organization reported in April 2024 that many lower-income countries had fewer than ten skilled rehabilitation practitioners per million residents. Equipment cannot address that gap without implementation support and dependable local maintenance across active installations. Manufacturers must provide training and service models that sustain utilization beyond an initial demonstration period. Facilities otherwise carry capital costs without enough qualified treatment sessions to meet expected operating returns across routine schedules.

Connected care creates a verified opening for extending selected exercises beyond hospital walls without removing clinical oversight. The Centers for Medicare & Medicaid Services added three remote therapeutic monitoring codes to the United States 2026 therapy-services framework in March 2026 for qualified reporting and review. Comparable remote patient monitoring platforms show how scheduled data review can support follow-up across dispersed patients. Technology providers must define escalation rules and clinician responsibilities because automated feedback cannot manage neurological deterioration or unsafe movement independently.

Which country CAGRs are profiled in the neurorehabilitation technology market?

Country	CAGR
USA	8.8%
UK	9.7%
Germany	8.3%
Japan	8.6%
South Korea	7.3%

How do country-level CAGRs compare in the neurorehabilitation technology market?

The country CAGR rates span 2.4 percentage points from 7.3% to 9.7% across the complete forecast interval. The narrow spread shows broadly positive momentum, but the spacing reflects different payment routes and service structures rather than equivalent current market size.

• The UK forms the upper comparison band through coordinated public pathways and established community rehabilitation planning. Its separation from the USA measures 0.9 percentage point, which can influence supplier expectations for multi-site procurement without proving a larger current revenue base.
• The USA and Japan sit within 0.2 percentage point of each other despite different commercial systems. American adoption depends on insurer documentation and institutional budgets, whereas Japanese adoption benefits from concentrated recovery wards with narrower approved treatment pathways.
• Germany remains 0.3 percentage point below Japan and 0.5 point below the USA during the forecast comparison. Its large rehabilitation facility network supports equipment utilization, yet dispersed ownership increases service distance and training costs across regional purchasing organizations.
• South Korea sits 1.0 percentage point below Germany and creates the lower comparison band within the displayed country set. Selective reimbursement can support defined robotic procedures, although additional platforms require separate evidence and coverage decisions until institutions can commit routine budgets.

Country entry plans should begin with the local payment unit and the organization responsible for operator training. A favorable CAGR cannot offset weak maintenance coverage or unclear patient eligibility across purchasing institutions. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• United States rehabilitation providers purchase regulated systems through hospital capital budgets and coded therapy services requiring complete clinical documentation. Demand for neurorehabilitation technology in the USA is forecast to rise at 8.8% CAGR through 2036, supported by provider networks and device-review routes. The Centers for Medicare & Medicaid Services reported in March 2026 that the national KX modifier threshold was USD 2,480 for combined physical and speech-language therapy services and separately for occupational therapy. Regional clinical and technical teams create a direct service route for multistate institutional rehabilitation programs. Coverage variation across insurers remains a material friction for projected equipment utilization across provider settings. Hospitals should confirm patient indications and service response times before approving a long-term investment model.
• England organizes stroke rehabilitation through integrated delivery networks and a seven-day community service connecting hospital discharge with home-based care. The UK neurorehabilitation technology market is forecast to record 9.7% CAGR from 2026 to 2036 through coordinated public pathways. Hocoma lists Brighthedge as its United Kingdom service partner for several gait and upper-limb systems. NHS England reported in December 2025 that around 80,000 people experience a stroke across England each year. Tyromotion states that regional partners can arrange institutional financing through established local commercial channels nationwide. Coordinated pathways provide a direct adoption enabler but public procurement requires evidence of capacity or functional improvement. Suppliers need durable training plans as responsibility shifts from acute hospitals toward community rehabilitation teams.
• Germany combines a rehabilitation facility base with decentralized ownership across public and private provider networks. The German neurorehabilitation technology market is estimated to advance at 8.3% CAGR between 2026 and 2036 through established institutional treatment capacity. Destatis reported in September 2025 that Germany operated 1,067 prevention or rehabilitation facilities with 160,697 beds during 2024. The institutional base creates a direct utilization enabler across neurological treatment networks and purchasing groups. Tyromotion maintains a German contact route and structured service packages across the DACH operating region. Distributed ownership remains a material friction because technician travel and clinician training must remain dependable across distant facilities. Rehabilitation providers should confirm regional service coverage and financing terms before approving multi-device capital programs.
• Japan’s hospitals concentrate neurological rehabilitation in dedicated wards with multidisciplinary staffing across the hospital system. Demand for neurorehabilitation technology in Japan is predicted to advance at 8.6% CAGR through 2036, supported by recovery wards. Eligible Medical HAL treatment receives public reimbursement under defined Japanese neurological indications across medical facilities. The Ministry of Health, Labour and Welfare reported in June 2025 that about 95,000 recovery beds operated across 1,620 institutions during 2023. Concentrated wards support adoption but fitting requirements and narrow reimbursement indications constrain demand across hospitals. CYBERDYNE provides required safety training and continuing education for clinical operators across qualified treatment institutions. Facilities should confirm approved indications and training capacity before forecasting robotic utilization across scheduled treatment programs.
• South Korean hospitals evaluate complex rehabilitation procedures through national health-technology review and selective reimbursement decisions. Demand for neurorehabilitation technology in South Korea is forecast to rise at 7.3% CAGR during the forecast period, supported by review pathways for systems. Hocoma lists JUNGWOO Trade as the local sales and service partner for several institutional systems. The local partner route creates a direct maintenance enabler for hospitals operating complex rehabilitation equipment. The Health Insurance Review & Assessment Service published coverage criteria in March 2026 for electromyography-driven hand robot-assisted rehabilitation under clinical conditions. Coverage remains limited to approved equipment and defined patients which restricts broader platform access across institutions nationally. Distributors need evidence packages addressing approval and clinical training within each selected national reimbursement route.

Who are the notable companies in the neurorehabilitation technology market?

DIH through Hocoma, Tyromotion, Fourier Rehab, CYBERDYNE, Lifeward, Ekso Bionics, MindMaze Therapeutics, and Neuro Rehab VR are notable companies shaping this market.

The competitive field combines broad rehabilitation ecosystems with focused wearable systems and software-led therapy platforms across clinical and home settings. Robotic portfolio companies compete through treatment coverage and integration support across several neurological conditions and facility types. Wearable developers compete through mobility training and regulatory access within clinical or personal pathways that require distinct support models. MindMaze Therapeutics reported in April 2026 that its United States commercial expansion covered hospital and outpatient programs alongside home-based neurotherapy. The adjacent medical robots field provides a useful comparison for safety responsibilities and service economics across regulated clinical equipment. Commercial selection depends on verified pathway fit and dependable local service rather than corporate scale.

• DIH through Hocoma and Tyromotion provide broad robotic portfolios with clinical integration and technical support across institutional rehabilitation settings. Fourier Rehab adds upper-limb and gait systems through an integrated digital hub that connects several therapy devices and supports coordinated clinical reporting.
• CYBERDYNE focuses on wearable gait systems with required professional training and region-specific indications across qualified clinical institutions. Ekso Bionics provides clinic-based exoskeletons with specialist support for institutional rehabilitation programs across active treatment centers. Lifeward combines clinical and personal mobility products through operating teams in the United States and Germany.
• MindMaze Therapeutics and Neuro Rehab VR emphasize software-led treatment and immersive practice across clinical or home environments. Comparable eldercare assistive robots show why usability and support become central as therapy extends beyond specialist departments into community and home environments.

Competitive Benchmarking: Neurorehabilitation Technology Market

Company	Robotic Motor Training	Digital Therapy and Measurement	Care-Pathway Support	Geographic Reach
DIH through Hocoma	High	High	High	Global
Tyromotion	High	High	High	Global
Fourier Rehab	High	High	Medium	Global
CYBERDYNE	High	Medium	High	Global
Lifeward	High	Medium	High	North America, Europe, and Israel
Ekso Bionics	High	High	High	Global
MindMaze Therapeutics	Low	High	Medium	Global
Neuro Rehab VR	Low	High	Medium	United States

Scoring basis: Robotic Motor Training is High for two or more dedicated powered systems and Medium for one proprietary powered platform. Low applies when official current portfolios remain limited to software or immersive therapy without proprietary powered movement assistance. Digital Therapy and Measurement is High for longitudinal assessment and Medium for structured session feedback. Low applies when official materials establish movement hardware without repeatable digital measurement across scheduled treatment sessions. Care-Pathway Support is High for documented training and maintenance and Medium for structured implementation onboarding services. Low applies when official materials restrict support to self-guided resources without technical maintenance or clinical onboarding. Geographic Reach records Global for documented multi-region operations and names narrower regions whenever official evidence confirms limited coverage.

Source basis: Official product and service pages support each rating together with current regulatory records and verified operating information.

Key Developments in the Neurorehabilitation Technology Market

• In May 2026, ChronoScale Corporation: the board committed to a plan to divest its wholly owned Ekso Bionics subsidiary and focus operations on its cloud business. A July 2026 holding-company transaction made ChronoScale Holdings Corporation the publicly traded parent of ChronoScale Corporation. Hospitals should verify whether the announced Ekso divestiture changes service continuity or parts responsibilities before expanding installed rehabilitation programs.
• In March 2025, Lifeward: the United States Food and Drug Administration cleared the ReWalk 7 personal exoskeleton for individuals with spinal cord injury. The company linked United States sales to product availability while practical access remained dependent on assessment and training. Reimbursement approval through applicable payer pathways continues to determine whether eligible users can obtain the cleared system.
• In January 2025, CYBERDYNE obtained Japanese manufacturing and marketing approval for the small-size Medical HAL Lower Limb Type B. The approved configuration extends Cybernics Treatment access to patients approximately 100 to 150 centimeters tall who could not use the standard model. Facilities must confirm eligible neurological indications and complete required operator training before incorporating the approved configuration into routine treatment.
• In June 2025, Fourier Rehab signed a strategic memorandum with Brooks Rehabilitation to study ArmMotus EMU and ExoMotus M4 in Florida. The collaboration places upper-limb and gait systems inside a specialist clinical environment for structured protocol development. Researchers can evaluate performance without treating technical study activity as proof of broader commercial adoption.

Key Players in the Neurorehabilitation Technology Market

Integrated Rehabilitation Robotics Providers

• DIH through Hocoma
• Tyromotion
• Fourier Rehab

Wearable Mobility and Exoskeleton Providers

• CYBERDYNE
• Lifeward
• Ekso Bionics

Digital and Immersive Neurotherapy Providers

• MindMaze Therapeutics
• Neuro Rehab VR

Neurorehabilitation Technology Market - Report Scope

Coverage field	Report scope
Market breakdown	Technology, application, end user, product type, and region.
Quantitative Units	USD million
Market Definition	Commercial hardware and associated software or services used directly to support neurological rehabilitation assessment and therapy delivery.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa.
Countries Covered	USA, UK, Germany, Japan, South Korea, and more than 30 countries within the complete report.
Key Companies Profiled	DIH through Hocoma, Tyromotion, Fourier Rehab, CYBERDYNE, Lifeward, Ekso Bionics, MindMaze Therapeutics, Neuro Rehab VR.
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing with segment and country validation across the defined revenue boundary.

Neurorehabilitation Technology Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Neurorehabilitation Technology Market by Segments

Neurorehabilitation Technology Market segmented by Technology:

• Robotic Rehabilitation
• Brain-Computer Interfaces
• Neurostimulation Systems
• Virtual Reality Rehabilitation

Neurorehabilitation Technology Market segmented by Application:

• Stroke Rehabilitation
• Spinal Cord Injury Rehabilitation
• Traumatic Brain Injury Rehabilitation
• Parkinson's Disease Rehabilitation

Neurorehabilitation Technology Market segmented by End User:

• Hospitals
• Rehabilitation Centers
• Specialty Clinics
• Home Care Settings

Neurorehabilitation Technology Market segmented by Product Type:

• Hardware
• Software
• Services
• Wearables

Neurorehabilitation Technology Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• NHS England. (2025, December 2). ‘Life-changing’ AI support helping stroke patients get a second chance.
• World Health Organization. (2025, May 2). OpenTeleRehab: a success story of inclusive telerehabilitation.
• Fiedorova, I., Banikova, S., Adamec, T., Konde, A., Hanzlikova, P., Ganesh, A., Bar, M., & Volny, O. (2026, January 1). Robot-assisted gait therapy in the subacute phase of ischemic stroke: A randomized controlled trial. Annals of Indian Academy of Neurology, 29(1), 52-58.
• World Health Organization. (2024, April 22). Rehabilitation.
• World Health Organization. (2024, March 14). Over 1 in 3 people affected by neurological conditions, the leading cause of illness and disability worldwide.
• Centers for Disease Control and Prevention. (2024, October 24). Stroke facts.
• Centers for Medicare & Medicaid Services. (2026, March 10). Therapy services.
• Centers for Medicare & Medicaid Services. (2026, June 5). Comprehensive outpatient rehabilitation facility services.
• USA Food and Drug Administration. (2026, June 16). Augmented reality and virtual reality in medical devices.
• NHS England. (n.d.). NHS England’s work on stroke.
• NHS England. (2022, February 28). National service model for an integrated community stroke service.
• Statistisches Bundesamt (Destatis). (2025, September 10). Vorsorge- oder Rehabilitationseinrichtungen 2024 nach Trägern und Bundesländern [Prevention or rehabilitation facilities in 2024 by ownership and federal state].
• Ministry of Health, Labour and Welfare. (2025, June 13). [Minutes of the third 2025 inpatient and outpatient care survey and evaluation subcommittee].
• Health Insurance Review & Assessment Service. (2026, March 5). [Electromyography-driven hand robot-assisted rehabilitation treatment].
• Hocoma. (n.d.). Sales and service partners.
• Hocoma. (n.d.). Lokomat product training.
• Hocoma. (n.d.). Technical services.
• Tyromotion. (n.d.). Rehabilitation equipment overview.
• Tyromotion. (n.d.). Service & support.
• Tyromotion. (n.d.). FAQ.
• Fourier Rehab. (n.d.). The most advanced rehabilitation robots.
• Fourier Rehab. (2025, June 3). Fourier Rehab and Brooks Rehabilitation sign strategic MOU to advance research in robotic neurorehabilitation.
• CYBERDYNE. (n.d.). Medical HAL - Lower Limb Type.
• CYBERDYNE. (n.d.). Medical HAL - Single Joint Type.
• CYBERDYNE. (2025, January 31). Notice of medical device approval for small-size model of Medical HAL in Japan.
• CYBERDYNE. (2016, June 23). Under the supervision of medical professionals, the manual for proper usage of HAL® for Medical Use (Lower Limb Type) has now been published: Commencement of the world’s first insured robotic treatment covered under general public health insurance.
• Lifeward. (2025, March 13). FDA issues clearance for ReWalk 7 exoskeleton.
• ChronoScale Corporation. (2026, June 4). Current report (Form 8-K).
• ChronoScale Holdings Corporation. (2026, July 8). Registration statement (Form S-8).
• MindMaze Therapeutics. (2026, April 15). MindMaze Therapeutics publishes 2025 annual report and corporate update.
• MindMaze Therapeutics. (n.d.). MindMotion GO - neurorehabilitation across the continuum of care.
• MindMaze Therapeutics. (n.d.). Contact MindMaze Therapeutics.
• Neuro Rehab VR. (n.d.). Information about our XR therapy system.
• Neuro Rehab VR. (2024, March 8). Why is onboarding and training important for VR for rehab?

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the neurorehabilitation technology market during 2026 and how does valuation change through 2036?
• Which operating conditions support the 8.1% CAGR across major neurological rehabilitation technology categories through 2036?
• Why does robotic rehabilitation hold the main technology position and what constrains usable clinical capacity?
• How do stroke pathways influence demand across hospitals and rehabilitation centers within different national systems?
• Which country growth rates are profiled for the USA and UK alongside Germany and Japan and South Korea?
• How do notable companies differ across robotics and digital therapy alongside pathway support and geographic reach worldwide?
• Which reimbursement and workforce conditions limit adoption despite technically capable rehabilitation equipment?
• What recent approvals and partnerships affect competitive development across wearable and institutional therapy systems?
• Which commercial checks support investment decisions across implementation and training alongside maintenance and outcome measurement?